Disc Medicine reports 'sun allergy' drug hits Phase 3 home run

Disc Medicine’s treatment for a rare disease that causes painful sun exposure succeeded on all endpoints in a Phase 3 study, according to Endpoints News.

Mabwell will present Phase II clinical data at the 2026 European Society for Medical Oncology (ESMO) Congress regarding its Nectin-4-targeting antibody-drug conjugate, 9MW2821. The study evaluated the efficacy and safety of 9MW2821 as a monotherapy or in combination with a PD-1 monoclonal antibody in patients with locally advanced or metastatic triple-negative breast cancer who were previously treated with a Topo I ADC.

The Vietnam Investment Review reports that as of April 10, 2026, among 60 efficacy-evaluable patients, the objective response rate was 30.0% and the disease control rate was 80.0%. The median progression-free survival was 3.7 months, the median duration of response was 8.7 months, and the median overall survival was not yet mature. No new safety signals were observed, and the results indicate a manageable safety profile.

Brief written by urgent.news from Endpoints News, Vietnam Investment Review — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.